表皮生長因子受體突變合并程序性細胞死亡蛋白1配體高表達的晚期肺腺癌病例報告_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 王麗雯 ¹ , 柯華 ^1,2 , 王可 ¹

1. ;
2. ;

Corresponding?author：

王麗雯, Email: 2750265469@qq.com

Keywords：

DOI：

10.7507/1671-6205.202309046

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王麗雯, 柯華, 王可. 表皮生長因子受體突變合并程序性細胞死亡蛋白1配體高表達的晚期肺腺癌病例報告. Chinese Journal of Respiratory and Critical Care Medicine, 2024, 23(9): 651-654. doi: 10.7507/1671-6205.202309046 Copy

1.	Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011, 29(21): 2866-2874.
2.	Soria JC, Ohe Y, Vansteenkiste J, et al. , Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2018, 378(2): 113-125.
3.	李詠生, 孫建國, 李夢俠, 等. 第三代EGFR-TKI耐藥后診療策略專家共識. 中華肺部疾病雜志(電子版), 2023, 16(2): 145-155.
4.	Liu WJ, Wang L, Zhou FM, et al. Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC. Drug Resist Updat, 2023, 70: 100987.
5.	Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer, 2019, 18(1): 165.
6.	Su S, Dong ZY, Xie Z, et al. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. J Thorac Oncol, 2018, 13(11): 1668-1675.
7.	Hsu KH, Huang YH, Tseng JS, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment na?ve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer, 2019, 127: 37-43.
8.	Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med, 2023, 11(7): 624-636.
9.	Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med, 2019, 7(5): 387-401.

1. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011, 29(21): 2866-2874.
2. Soria JC, Ohe Y, Vansteenkiste J, et al. , Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2018, 378(2): 113-125.
3. 李詠生, 孫建國, 李夢俠, 等. 第三代EGFR-TKI耐藥后診療策略專家共識. 中華肺部疾病雜志(電子版), 2023, 16(2): 145-155.
4. Liu WJ, Wang L, Zhou FM, et al. Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC. Drug Resist Updat, 2023, 70: 100987.
5. Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer, 2019, 18(1): 165.
6. Su S, Dong ZY, Xie Z, et al. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. J Thorac Oncol, 2018, 13(11): 1668-1675.
7. Hsu KH, Huang YH, Tseng JS, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment na?ve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer, 2019, 127: 37-43.
8. Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med, 2023, 11(7): 624-636.
9. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med, 2019, 7(5): 387-401.

Chinese Journal of Respiratory and Critical Care Medicine

表皮生長因子受體突變合并程序性細胞死亡蛋白1配體高表達的晚期肺腺癌病例報告

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content